Table 1.
Patient demographics
| Variables | n=244 |
|---|---|
| Recipient characteristics | |
| Men, n (%) | 150 (61.5) |
| Age (yr) at transplantation, mean±SD | 46.5±16.5 |
| Cause of ESRD, n (%) | |
| GN | 53 (21.8) |
| Diabetes | 22 (9.1) |
| Cystic/hereditary/congenital | 42 (17.3) |
| Secondary GN | 10 (4.1) |
| Hypertension | 22 (9.1) |
| Interstitial nephritis | 42 (17.3) |
| Miscellaneous conditions | 8 (3.3) |
| Neoplasm | 0 (0.0) |
| Etiology uncertain | 44 (18.1) |
| Transplant variables | |
| Donor age (yr), mean±SD | 54.8±17.3 |
| Deceased donor, n (%) | 187 (76.6) |
| Living donor, n (%) | 57 (23.4) |
| Expanded criteria donor,a n (%) | 94 (51.6) |
| Retransplantation, n (%) | 42 (17.2) |
| Cold ischemia time (h),a mean±SD | 21.8±7.7 |
| Delayed graft function,a n (%) | 62 (34.3) |
| Preformed DSAs with MFI>1000,b n (%) | 67 (33.7) |
| Immunosuppressive protocol | |
| Induction therapy, n (%) | 220 (98.7) |
| Basiliximab/thymoglobuline, n (%) | 116 (52.7)/104 (47.3) |
| Calcineurin inhibitor–based therapy, n (%) | 223 (91.4) |
| Cyclosporin/tacrolimus, n (%) | 51 (22.9)/172 (77.1) |
| Purine synthesis inhibitor, n (%) | 229 (93.9) |
| Azathioprine/mycophenolic acid, n (%) | 15 (6.6)/214 (93.4) |
| Mammalian target of rapamycin inhibitor, n (%) | 16 (6.6) |
| Steroid, n (%) | 232 (95.1) |
| Outcome | |
| Serum creatinine (µmol/L) at last follow-up, mean±SD | 206±157 |
| Patient survival at last follow-up, n (%) | 233 (95.5) |
| Graft survival at last follow-up, n (%) | 215 (88.1) |
| Mean follow-up (d), mean±SD | 1914±1762 |
a
In deceased donor grafts only.
b
Assessment of DSAs in 229 kidney transplant recipients.